STOCK TITAN

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company, announced on March 3, 2021 that its CEO, Jeffrey Eisenberg, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing its XCART™ technology, designed to target specific neoantigens in tumors. A video presentation will be available on-demand starting March 9, 2021, at 7:00 AM ET. Xenetic is known for developing personalized CAR T therapies for B-cell lymphomas and utilizing its PolyXen® platform to enhance drug delivery.

Positive
  • None.
Negative
  • None.

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website here.

The video webcast presentation will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the IR Calendar page of the Investors section of the Company's website (xeneticbio.com).

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.



View source version on accesswire.com:
https://www.accesswire.com/633068/Xenetic-Biosciences-Inc-to-Present-at-the-HC-Wainwright-Global-Life-Sciences-Conference

FAQ

What is the date of Xenetic Biosciences' presentation at the H.C. Wainwright Global Life Sciences Conference?

Xenetic Biosciences' presentation is scheduled for March 9-10, 2021.

Who is presenting for Xenetic Biosciences at the conference?

Jeffrey Eisenberg, the CEO of Xenetic Biosciences, will present at the conference.

What technology does Xenetic Biosciences focus on?

Xenetic Biosciences focuses on advancing its XCART™ technology, which targets patient- and tumor-specific neoantigens.

When will the video webcast of Xenetic's presentation be available?

The video webcast will be available on-demand starting March 9, 2021, at 7:00 AM ET.

What does XCART™ technology aim to treat?

XCART™ technology aims to treat B-cell lymphomas through personalized CAR T therapies.

Xenetic Biosciences, Inc.

NASDAQ:XBIO

XBIO Rankings

XBIO Latest News

XBIO Stock Data

6.60M
1.54M
19.03%
0.97%
1.09%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FRAMINGHAM